Value Sense
ABT
Abbott Laboratories (ABT)
Last Price$132.7(3.4%)
Market Cap$231.4B
LTM EPS
$7.74
EPS growth
(33.4%)
Ben Graham Fair Value
($387.3)
Overvalued (Ben Graham formula)
(392.0%)
Stock quality
7/10
Great
ABT
is 34.3% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

ABT Ben Graham Fair Value

Ben Graham Fair Value
Ben Graham Revised Fair Value

Ben Graham Fair Value Assumptions

as of Mar 12, 2025
EPS
$7.74
P/E Base for no-growth company
8.5x
EPS growth
(33.4%)
Average Yield of AAA Corporate Bonds
4.4%
Current Yield of AAA Corporate Bonds
5.1%
Last share price
$132.7
Ben Graham Fair Value (local)
($387.3)
Ben Graham Fair Value
($387.3)
392% overvalued

Ben Graham Fair Value Calculation

EPS
$7.74
x
(
P/E base for no-growth
8.5x
+
2
x
EPS growth
(33.4%)
)
x
Average AAA
Bond Yield
4.4%
/
Current AAA Bond Yield
5.1%
=
Ben Graham Fair Value
($387.3)

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

ABT EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

ABT vs Peer Set: Ben Graham Fair Value Comparison

Ben Graham Fair Value
Ben Graham Revised Fair Value

GENERAL

BEN GRAHAM FAIR VALUE

FINANCIALS

Company name

Undervaluation / Overvaluation

Revenue growth

EPS growth

Net Income margin

Abbott Laboratories logo
Abbott LaboratoriesABT
(392.0%)
4.6%
134.5%
31.9%
Median Peer Set
4.3%
7.6%
11.6%
Smith & Nephew plc logo
Smith & Nephew plcSNN
1,309.2%
4.7%
(21.7%)
7.1%
Koninklijke Philips N.V. logo
Koninklijke Philips N.V.PHG
1,131.5%
(0.8%)
122.5%
(3.9%)
Medtronic plc logo
Medtronic plcMDT
513.5%
3.6%
(2.1%)
11.4%
STERIS plc logo
STERIS plcSTE
406.2%
3.6%
257.9%
7.4%
Zimmer Biomet Holdings, Inc. logo
Zimmer Biomet Holdings, Inc.ZBH
360.5%
3.8%
(9.4%)
11.8%
Boston Scientific Corporation logo
Boston Scientific CorporationBSX
196.9%
17.6%
16.7%
11.1%
DexCom, Inc. logo
DexCom, Inc.DXCM
66.8%
11.3%
(1.4%)
14.3%
Stryker Corporation logo
Stryker CorporationSYK
(99.6%)
10.2%
(5.8%)
13.2%
Insulet Corporation logo
Insulet CorporationPODD
(206.5%)
22.1%
101.7%
20.2%
Edwards Lifesciences Corporation logo
Edwards Lifesciences CorporationEW
(1,161.0%)
(9.4%)
202.2%
76.7%

Explore more intrinsic value tools hub for ABT

Peter Lynch Fair Value
Reverse DCF
Earnings growth model
Earnings Power Value
Discount rate
Relative Value
Intrinsic Value
Margin of safety
DCF value calculator
Peter Lynch charts

FAQ

What is Abbott Laboratories's fair value according to the Ben Graham formula?

As of Dec 31, 2024, Abbott Laboratories's fair value using the Ben Graham formula is ($387.3) per share. This is calculated using Ben Graham formula, where EPS is $7.7 and BVPS (Book Value Per Share) is $27.4. The current price of $132.7 suggests Abbott Laboratories may be overvalued by this conservative metric.

What is Abbott Laboratories earnings per share (EPS)?

Abbott Laboratories earnings per share (EPS) for the twelve months ending Dec 31, 2024, was $7.7, a (33.4%) growth year-over-year.

What is Abbott Laboratories's margin of safety based on the Ben Graham analysis?

Abbott Laboratories's margin of safety is negative 392.0%, calculated as (Graham Number - Current Price) / Current Price. A negative margin of safety suggests the stock doesn't provide the level of safety Graham typically sought in his investments.